Serge A. Jabbour, MD

Serge Jabbour, MD, FACP, FACE
 

Professor of Medicine
Thomas Jefferson University
Division of Endocrinology, Diabetes and Metabolic Diseases
Department of Medicine
Jefferson Medical College
Philadelphia, Pennsylvania


What is the physiological, safety, efficacy and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? How does this impact FPG and PPG control?

What is the physiological, safety, efficacy and compliance-focused rationale for combining basal insulin plus GLP-1 RA into a fixed ratio formulation? And how does this strategy impact pan-glycemic—FPG and PPG—control?

Can you identify the specific composition of fixed ratio combination long-acting insulin/GLPA-1 RA formulations, and how clinicians should titrate and deploy these agents?

Can you identify the specific composition of fixed ratio combination long-acting insulin/GLPA-1 RA formulations, and how clinicians should titrate and deploy these agents?

How would approach a mildly obese patient with T2D on a maximum dose of metformin who is not yet achieving FPG or PPG target goals?

How would approach a mildly obese patient with T2D on a maximum dose of metformin who is not yet achieving FPG or PPG target goals?

How would you approach a 65-year old patient with T2D who has reasonable control of FBG but clear documentation of PPG?

How would you approach a 65-year old patient with T2D who has reasonable control of FBG but clear documentation of PPG?

What level of HA1c reduction is achieved with the fixed ratio combination and how is the side effect profile of the GLP-1 RA affected by the combination formulation and the titration strategy it utilizes?

What level of HA1c reduction is achieved with the fixed ratio combination and how is the side effect profile of the GLP-1 RA affected by the combination formulation and the titration strategy it utilizes?

From a practical, titration perspective what important clinical guidance can you provide to optimize effectiveness of the fixed ratio insulin-GLP-1 RA combination?

From a practical, titration perspective what important clinical guidance can you provide to optimize effectiveness of the fixed ratio insulin-GLP-1 RA combination?